Inhibits NNMT and reduces its methylated nicotinamide product in experimental systems.
Metabolic & mitochondrial research
5-Amino-
1MQ.
A research profile of 5-amino-1-methylquinolinium, a small-molecule inhibitor used to investigate nicotinamide N-methyltransferase and metabolic regulation.
Research contextThis page summarises published laboratory findings. It does not establish human benefit, safety, dosing or suitability for personal use.
Description
What is 5-Amino-1MQ?
5-Amino-1MQ is the abbreviated name for 5-amino-1-methylquinolinium. Despite often appearing in peptide catalogues, it is a small organic molecule rather than a peptide. It was developed as a membrane-permeable inhibitor of NNMT, an enzyme that transfers a methyl group from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide.
NNMT connects nicotinamide handling with the cellular methyl-donor pool. Because these processes intersect with NAD metabolism, epigenetic regulation and energy balance, the enzyme has become an experimental target in metabolic research. Published work on 5-Amino-1MQ is primarily preclinical.
Mechanism under study
NNMT inhibition,
carefully examined.
5-Amino-1MQ binds to and inhibits NNMT. In cultured adipocytes, researchers reported reduced formation of the NNMT product 1-methylnicotinamide alongside changes in intracellular NAD+ and S-adenosylmethionine. These biochemical changes were studied in relation to lipid synthesis and energy metabolism.
Allows researchers to examine how altered NNMT activity intersects with NAD-related cellular chemistry.
Supports investigation of relationships among NNMT, SAM and methylation-dependent processes.
Used in cell and mouse models to study adipocyte metabolism, glucose handling and liver-associated changes.
Areas studied
Current research
questions.
Cell studies have examined intracellular 1-MNA, NAD-related metabolites and lipid synthesis following NNMT inhibition.
Diet-induced-obesity mouse models have been used to investigate body composition and adipose-tissue responses.
Animal studies have reported changes in glucose tolerance, insulin sensitivity and circulating metabolic markers.
Recent mouse research has examined fatty-liver pathology and the tissue distribution of 5-Amino-1MQ.
Potential side effects
Reported effects.
Evidence clearly labelled.
An established human side-effect profile is not available for 5-Amino-1MQ. Headache, mild fatigue, digestive discomfort, nausea, a mild increase in heart rate, dizziness, jitteriness and temporary sleep disturbance are described by vendors or users, but these reports have not been confirmed or assigned a reliable frequency in controlled human trials.
Headache, fatigue, bloating, nausea, a faster heartbeat, dizziness, jitteriness and sleep disturbance have been described online. They should not be presented as clinically established “common” or “rare” effects.
Redness, irritation, itching or discomfort can occur with an injectable research preparation and may relate to the route, excipients, concentration, sterility or handling rather than the active compound alone.
NNMT inhibition intersects with nicotinamide and methyl-donor metabolism. Human interactions, reproductive risk, liver or kidney effects, cardiovascular effects and long-term toxicity remain unknown.
Suggestions to reduce, split or otherwise alter a dose are treatment instructions unsupported by controlled human evidence and are deliberately excluded from this research reference.
Evidence limits
What the evidence
does not show.
The prominent findings for 5-Amino-1MQ come from biochemical assays, cultured cells and mouse models. Results from these systems cannot be assumed to demonstrate the same effects, safety profile or exposure in people.
This page deliberately avoids describing preclinical outcomes as human “benefits.” There is no established clinical dosing information here, and the profile should not be used to guide personal use or healthcare decisions.
Selected reading
Published
sources.
These links are provided so readers can examine the underlying methods, models and limitations directly. The vendor reference is identified separately and is not treated as clinical evidence.
Neelakantan et al. — Selective and membrane-permeable small molecule inhibitors of NNMT reverse high-fat-diet-induced obesity in mice ↗Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction ↗Review — Mechanisms and inhibitors of nicotinamide N-methyltransferase ↗Vendor reference reviewed for anecdotal reports — not clinical evidence ↗
← Return to the A–Z research library